Financial Summary for the Fiscal Year Ending December 2025 [IFRS] (Consolidated)

Performance Overview

For the fiscal year ending December 2025, consolidated revenue totaled JPY 2,468.892 billion (6.0% YoY increase), driven by increased sales of the antipsychotic 'Rexulti', anti-cancer agent 'Lonsurf', and the extended-release injection 'Abilify' series in the medical-related segment. Business profit was JPY 446.129 billion (3.6% YoY increase), and operating income increased significantly to JPY 479.375 billion (48.2% YoY increase). The rise in operating income was due not only to higher business profit but also to gains on the sale of shares in MicroPort Scientific Corporation and a substantial reduction in impairment losses. Net income attributable to owners of parent was JPY 363.150 billion (5.8% YoY increase). Research and development expenses were JPY 352.838 billion (12.3% YoY increase), reflecting increased investments in the development of new antipsychotic drugs and non-small cell lung cancer treatments.

Segment Performance and Future Outlook

Revenue in the medical-related segment amounted to JPY 1,744.234 billion (7.1% YoY increase), with business profit of JPY 402.016 billion (2.9% YoY increase). The nutraceuticals-related segment recorded revenue of JPY 577.669 billion (3.7% YoY increase), and business profit of JPY 68.970 billion (7.4% YoY increase), maintaining steady growth. The consumer-related segment posted revenue of JPY 34.634 billion (2.6% YoY increase) and business profit of JPY 25.171 billion (6.4% YoY increase). For the fiscal year ending December 2026, revenue is projected at JPY 2,520 billion (2.1% YoY increase), while business profit is forecasted to decline to JPY 355 billion (20.4% YoY decrease), primarily due to the impact of generic drugs in the medical-related segment and aggressive investments in growth products. Annual dividends are expected to remain at 140 JPY.